News

Integrating IoT devices within healthcare systems allows professionals and individuals to have access to new health-related data used for informed, personalized healthcare applications and situations.

Soon after FDA warned about a potential increased risk of foot and leg amputations with the use of the type 2 diabetes medication canagliflozin (Invokana and Invokamet, Janssen Biotech), the agency strengthened the existing warning about the risk of acute kidney injury with Invokana and Invokamet, as well as dapagliflozin (Farxiga and Xigduo XR, AstraZeneca).

The ER Savings Initiative is designed to deliver care in a hybrid model that collaborates with health systems to eliminate the unnecessary use and costs of their ERs.

Teva Pharmaceuticals is temporarily suspending sales and distribution of its sumatriptan iontophoretic transdermal system (Zecuity) patch for migraines, after FDA said it is investigating the risk of serious burns with the use of the patch.

FDA approved the first US vaccine for cholera, Vaxchora, made by PaxVax Bermuda Ltd. in Hamilton, Bermuda. Vaxchora is the only single-dose vaccine for cholera currently licensed anywhere in the world.

Precision medicine isn’t just about genomics anymore. With the field moving forward as the next step in population health management, environmental, social and lifestyle factors that live outside the medical system are increasingly important to target treatments and engage patients. That means health plans also need innovative technology solutions to capture, store and integrate this crucial information.

Physicians need to be well-versed in the evolving government requirements for billing, reimbursement and overall healthcare delivery/patient experience. One expert outlines these important items for physicians to watch.

Humana's Bold Goal progress report aims to improve population health by addressing health barriers, increasing access to healthcare, encouraging healthy behaviors, and promoting the prevention and management of chronic conditions prevention and management.

FDA is warning consumers about the risk of serious bleeding when using over-the-counter aspirin-containing antacid products to treat heartburn. The agency also issued a separate warning about loperamide (Imodium, Johnson & Johnson), saying that abuse or misuse of the product can cause serious heart problems that can lead to death.

The first and only fixed-dose combination of a beta blocker beta blocker (BB) and angiotensin II receptor blocker (ARB) for hypertension will be available in the US in the second half of the year. FDA approved nebivolol and valsartan (Byvalson, Allergan) 5 mg/80 mg tablets in early June.